NCCN Guidelines® Insights: Breast Cancer, Version 4.2021-Reference-Cited by-同舟云学术

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021

Published:2021-05 Issue:5 Volume:19 Page:484-493
ISSN:1540-1405
Container-title:Journal of the National Comprehensive Cancer Network
language:
Short-container-title:

Author:

Gradishar William J.¹,Moran Meena S.²,Abraham Jame³,Aft Rebecca⁴,Agnese Doreen⁵,Allison Kimberly H.⁶,Blair Sarah L.⁷,Burstein Harold J.⁸,Dang Chau⁹,Elias Anthony D.¹⁰,Giordano Sharon H.¹¹,Goetz Matthew P.¹²,Goldstein Lori J.¹³,Hurvitz Sara A.¹⁴,Isakoff Steven J.¹⁵,Jankowitz Rachel C.¹⁶,Javid Sara H.¹⁷,Krishnamurthy Jairam¹⁸,Leitch Marilyn¹⁹,Lyons Janice³,Matro Jennifer¹⁶,Mayer Ingrid A.²⁰,Mortimer Joanne²¹,O'Regan Ruth M.²²,Patel Sameer A.¹³,Pierce Lori J.²³,Rugo Hope S.²⁴,Sitapati Amy⁷,Smith Karen Lisa²⁵,Smith Mary Lou²⁶,Soliman Hatem²⁷,Stringer-Reasor Erica M.²⁸,Telli Melinda L.⁶,Ward John H.²⁹,Wisinski Kari B.²²,Young Jessica S.³⁰,Burns Jennifer L.³¹,Kumar Rashmi³¹

Affiliation:

1. 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

2. 2Yale Cancer Center/Smilow Cancer Hospital;

3. 3Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

4. 4Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;

5. 5The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;

6. 6Stanford Cancer Institute;

7. 7UC San Diego Moores Cancer Center;

8. 8Dana-Farber/Brigham and Women’s Cancer Center;

9. 9Memorial Sloan Kettering Cancer Center;

10. 10University of Colorado Cancer Center;

11. 11The University of Texas MD Anderson Cancer Center;

12. 12Mayo Clinic Cancer Center;

13. 13Fox Chase Cancer Center;

14. 14UCLA Jonsson Comprehensive Cancer Center;

15. 15Massachusetts General Hospital Cancer Center;

16. 16Abramson Cancer Center at the University of Pennsylvania;

17. 17Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

18. 18Fred & Pamela Buffet Cancer Center;

19. 19UT Southwestern Simmons Comprehensive Cancer Center;

20. 20Vanderbilt-Ingram Cancer Center;

21. 21City of Hope National Medical Center;

22. 22University of Wisconsin Carbone Cancer Center;

23. 23University of Michigan Rogel Cancer Center;

24. 24UCSF Helen Diller Family Comprehensive Cancer Center;

25. 25The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

26. 26Research Advocacy Network;

27. 27Moffitt Cancer Center;

28. 28O'Neal Comprehensive Cancer Center at UAB;

29. 29Huntsman Cancer Institute at the University of Utah;

30. 30Roswell Park Comprehensive Cancer Center; and

31. 31National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Breast Cancer include up-to-date guidelines for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, male breast cancer, and breast cancer during pregnancy. These guidelines are developed by a multidisciplinary panel of representatives from NCCN Member Institutions with breast cancer–focused expertise in the fields of medical oncology, surgical oncology, radiation oncology, pathology, reconstructive surgery, and patient advocacy. These NCCN Guidelines Insights focus on the most recent updates to recommendations for adjuvant systemic therapy in patients with nonmetastatic, early-stage, hormone receptor–positive, HER2-negative breast cancer.

Publisher

Harborside Press, LLC

Subject

Oncology

Link

https://jnccn.org/downloadpdf/journals/jnccn/19/5/article-p484.xml

Cited by 187 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optical Emission Spectroscopy for the Real-Time Identification of Malignant Breast Tissue;Diagnostics;2024-02-04

2. HER2-targeted therapies in cancer: a systematic review;Biomarker Research;2024-02-02

3. Administration of Inhibitory Molecules through Nanoparticles in Breast Cancer Therapy;Current Medicinal Chemistry;2024-02

4. Risk factors for late recurrence and postrelapse survival in estrogen receptor (ER)-positive, human epidermal growth factor receptor (HER) 2-negative breast cancer after 5 years of endocrine therapy;The Breast;2024-02

5. Treatments and Prognosis of the Breast Ductal Carcinoma In Situ;Clinical Breast Cancer;2024-02